File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Peripheral T-cell lymphoma.

TitlePeripheral T-cell lymphoma.
Authors
Issue Date2002
Citation
Current Oncology Reports, 2002, v. 4 n. 5, p. 434-442 How to Cite?
AbstractPeripheral (post-thymic) T-cell lymphoma consists of a wide spectrum of disorders with marked differences in biology and behavior. Proper classification is pivotal for evaluating treatment results, and most studies performed a decade ago lump together different disease entities and cannot be interpreted. With improved use of immunophenotyping and molecular methods for these disorders, their exact nature is better defined in the Revised European-American Lymphoma and subsequent World Health Organization (WHO) classifications. The WHO classification of post- thymic T/natural killer (NK)-cell lymphoma consists of 15 entities, including about 30% that are unclassified cases. A wide range in incidence exists between different populations, but it is likely to be lower than previously estimated. Certain entities, like nasal/nasal-type T/NK-cell lymphoma and human T-cell leukemia/lymphoma virus 1, are much more prevalent in certain racial groups and show exquisite viral association. In these entities as a group, prognosis and treatment seem inferior to those of their B-cell counterparts, but treatment must be tailored to the exact pathologic diagnosis and prognostic index. Aggressive combination chemotherapy appears to be curative for certain entities (eg, anaplastic lymphoma kinase-positive), whereas purine analogues may be useful for low-grade entities. The role of autologous and allogeneic stem cell transplantation is still poorly defined. Specific antibody-based therapy is also on the horizon.
Persistent Identifierhttp://hdl.handle.net/10722/162628
ISSN
2015 Impact Factor: 2.653
2015 SCImago Journal Rankings: 1.158

 

DC FieldValueLanguage
dc.contributor.authorAu, WYen_US
dc.contributor.authorLiang, Ren_US
dc.date.accessioned2012-09-05T05:21:49Z-
dc.date.available2012-09-05T05:21:49Z-
dc.date.issued2002en_US
dc.identifier.citationCurrent Oncology Reports, 2002, v. 4 n. 5, p. 434-442en_US
dc.identifier.issn1523-3790en_US
dc.identifier.urihttp://hdl.handle.net/10722/162628-
dc.description.abstractPeripheral (post-thymic) T-cell lymphoma consists of a wide spectrum of disorders with marked differences in biology and behavior. Proper classification is pivotal for evaluating treatment results, and most studies performed a decade ago lump together different disease entities and cannot be interpreted. With improved use of immunophenotyping and molecular methods for these disorders, their exact nature is better defined in the Revised European-American Lymphoma and subsequent World Health Organization (WHO) classifications. The WHO classification of post- thymic T/natural killer (NK)-cell lymphoma consists of 15 entities, including about 30% that are unclassified cases. A wide range in incidence exists between different populations, but it is likely to be lower than previously estimated. Certain entities, like nasal/nasal-type T/NK-cell lymphoma and human T-cell leukemia/lymphoma virus 1, are much more prevalent in certain racial groups and show exquisite viral association. In these entities as a group, prognosis and treatment seem inferior to those of their B-cell counterparts, but treatment must be tailored to the exact pathologic diagnosis and prognostic index. Aggressive combination chemotherapy appears to be curative for certain entities (eg, anaplastic lymphoma kinase-positive), whereas purine analogues may be useful for low-grade entities. The role of autologous and allogeneic stem cell transplantation is still poorly defined. Specific antibody-based therapy is also on the horizon.en_US
dc.languageengen_US
dc.relation.ispartofCurrent oncology reportsen_US
dc.subject.meshHumansen_US
dc.subject.meshLymphoma, T-Cell, Peripheral - Classification - Diagnosis - Therapyen_US
dc.subject.meshPrognosisen_US
dc.titlePeripheral T-cell lymphoma.en_US
dc.typeArticleen_US
dc.identifier.emailLiang, R:rliang@hku.hken_US
dc.identifier.authorityLiang, R=rp00345en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.pmid12162919-
dc.identifier.scopuseid_2-s2.0-0036718847en_US
dc.identifier.hkuros77906-
dc.identifier.volume4en_US
dc.identifier.issue5en_US
dc.identifier.spage434en_US
dc.identifier.epage442en_US
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridAu, WY=7202383089en_US
dc.identifier.scopusauthoridLiang, R=26643224900en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats